 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FORT COLLINS, CO / ACCESSWIRE / January 24, 2023 / Statera Biopharma, Inc. (NASDAQ:STAB) (the 'Company' or 'Statera Biopharma'), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, is pleased to announce it has...

Statera Biopharma Announces Completion of Application Process to Uplist to the OTCQB(R) Venture Marketplace

Statera Biopharma, Inc. (NASDAQ:STAB Get Rating) saw a large decline in short interest in November. As of November 30th, there was short interest totalling 829,100 shares, a decline of 37.7% from the November 15th total of 1,330,000 shares. Based on an average daily volume of 3,530,000 shares, the ...

Statera Biopharma, Inc. (NASDAQ:STAB) Short Interest Down 37.7% in November

Statera Biopharma granted continued listing on Nasdaq

FORT COLLINS, CO / ACCESSWIRE / October 27, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the 'Company' or 'Statera Biopharma'), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that, by...

Statera Biopharma Receives Positive Nasdaq Listing Determination

Gainers
Statera BioPharma (NASDAQ:STAB) shares increased by 33.1% to $0.2 during Friday's pre-market session. The company's market cap stands at $10.4 million.

read more...

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers
Statera Biopharma, Inc. (NASDAQ: STAB) rose 40.9% to $0.2160 in pre-market trading. Statera Biopharma recently signed a binding Memorandum of Understanding with Holobeam Technologies Inc.

read more...

Why Snap Shares Are Trading Sharply Lower; Here Are 25 Stocks Moving Premarket

FORT COLLINS, CO / ACCESSWIRE / October 21, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the 'Company' or 'Statera Biopharma'), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the...

Statera Biopharma Files Form 10-Q and Reaches Agreement with Silverback Capital and AVOF

Statera Biopharma Shares Fall After Taking Stake In Holographic Medical Imaging

FORT COLLINS, CO / ACCESSWIRE / October 17, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the 'Company' or 'Statera Biopharma'), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the signing of...

Statera Biopharma Announces Signing of a Binding MOU with Holobeam Technologies to Gain Access to Holobeams Disruptive Diagnostic Imaging and Therapeutic Technology for Cancer Patients

Statera Biopharma, Inc. (NASDAQ:STAB  Get Rating) was the recipient of a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 439,200 shares, a drop of 42.1% from the September 15th total of 759,200 shares. Currently, 1.1% of the ...

Statera Biopharma, Inc. (NASDAQ:STAB) Short Interest Update

Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia. The firm is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.

Watchers	8,214
52-Wk Low	$0.0003
52-Wk High	$0.3047

Market Cap	$21,400.00
Volume (M)	2,895.00
52-Wk High	$0.3047
52-Wk Low	$0.0003

STAB Statera BioPharma Inc

About

Feed

News

Sentiment

Fundamentals